Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
68.93(c) 69.67(c) 69.56(c) 69.5(c) 69.48 Last
8 518 463 9 411 737 8 328 150 7 049 396 3 136 452 Volume
0.00% +1.07% -0.16% -0.09% -0.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 26 507 M - -
Net income 2021 7 187 M - -
Net Debt 2021 22 419 M - -
P/E ratio 2021 12,1x
Yield 2021 4,07%
Sales 2022 24 065 M - -
Net income 2022 6 360 M - -
Net Debt 2022 16 426 M - -
P/E ratio 2022 13,9x
Yield 2022 4,28%
Capitalization 87 180 M 87 180 M -
EV / Sales 2021 4,13x
EV / Sales 2022 4,31x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GILEAD SCIENCES, INC.
12/06Goldman Sachs Starts Gilead Sciences at Neutral With $80 Price Target
MT
12/04Gilead recalls vials of COVID-19 drug remdesivir due to glass contamination
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02DOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading
DJ
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/01GILEAD SCIENCES : Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
PU
11/30NRX Pharmaceuticals Shares Slide 16% After Soaring on COVID-19 Drug, Vaccine Updates
MT
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Regeneron's COVID-19 antibody drug may be less effective against Omicron
RE
11/30Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
AQ
11/29NRX Pharmaceuticals Soars After Saying Zyesami Outperformed Remdesivir for Critical COV..
MT
11/29Gilead Sciences Selects Amazon Web Services as Cloud Provider
MT
11/29Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
BU
11/24Gilead Sciences' Trodelvy (sacituzumab govitecan) Granted European Commission Marketing..
AQ
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
More news
News in other languages on GILEAD SCIENCES, INC.
11:37aROCHE : feu vert européen pour le tocilizumab contre le Covid-19
03:09aKempen zet Galapagos op kooplijst
12/03INTESA SANPAOLO : premia migliore startup innovativa a Pni 2021
12/02STARTUP : 16 i progetti finalisti per Pni 2021
11/30Les actions de NRX Pharmaceuticals chutent de 16% après avoir grimpé en flèche grâce au..
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 69,50 $
Average target price 76,14 $
Spread / Average Target 9,55%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137
BEIGENE, LTD.21.58%30 750